Thrombolytics: Difference between revisions

No edit summary
Line 2: Line 2:
{{Thrombolytics STEMI}}
{{Thrombolytics STEMI}}


===Indications and Contraindications<ref>Rivera-Bou WL et al. Thrombolytic therapy for acute myocardial infarction. Dec 08, 2015. http://emedicine.medscape.com/article/811234-overview#a3.</ref>===
==Thrombolysis indications and Contraindications==
*Indications<ref>ACLS Training Center. Fibrinolytic Checklist for STEMI. https://www.acls.net/images/algo-fibrinolytic.pdf</ref>
{{Thrombolysis indications and contraindications in STEMI}}
**[[Chest pain]] > 30 min but less than 12 hrs, not relieved by NTG
**PCI greater than 120 min away<ref> [AHA 2013 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction [https://www.heart.org/idc/groups/heart-public/@wcm/@mwa/documents/downloadable/ucm_453635.pdf PDF]</ref>
**[[ECG]] criteria of STEMI
***STE in 2 contiguous leads
***Posterior STEMI
***LBBB with Sgarbossa criteria
*Absolute contraindications
**Prior ICH
**Known cerebral vascular lesion, AVM
**Known intracranial malignancy, primary or mets
**Ischemic stroke within 3 months, but not ischemic stroke within 3 hrs
**Suspected aortic dissection
**Active bleeding or bleeding diathesis, excluding menses
**Significant closed head/facial trauma within 3 months
*Relative contraindications
**History of chronic, severe hypertension
**SBP > 180 or DBP > 110 mmHg
**History of prior ischemic stroke > 3 months, dementia, or other known intracranial pathology not in absolute contraindications
**Traumatic CPR or CPR > 10 min
**Major surgery within 3 wks
**Internal bleeding within 2-4 wks
**Noncompressible vascular punctures
**Prior allergic reactions to fibrinolytics
**Pregnancy
**Active PUD
**Use of anticoagulants


==[[Thrombolysis in Acute Ischemic Stroke (tPA)]]==
==[[Thrombolysis in Acute Ischemic Stroke (tPA)]]==

Revision as of 20:13, 16 February 2018

Thrombolytics in STEMI

Alteplase (TPA)

Dosing based on patient weight:

  • 67kg: Infuse 15mg IV over 1-2min; then 50mg over 30min; then 35mg over next 60min (i.e. 100mg over 1.5hr)
  • ≤67kg: Infuse 15mg IV over 1-2min; then 0.75 mg/kg (max 50mg) over 30 min; then 0.5 mg/kg over 60min (max 35 mg)

Tenecteplase (TNKase)

  • Reconstitute 50 mg vial in 10 mL sterile water (5 mg/mL)
  • < 60 kg = 30 mg IV push over 5 seconds
  • 60-69 kg = 35 mg IV push over 5 seconds
  • 70-79 kg = 40 mg IV push over 5 seconds
  • 80-89 kg = 45 mg IV push over 5 seconds
  • > 90 kg = 50 mg IV push over 5 seconds

Thrombolysis indications and Contraindications

Template:Thrombolysis indications and contraindications in STEMI

Thrombolysis in Acute Ischemic Stroke (tPA)

Alteplase

  • NOTE - in stroke, do not give aspirin until 24 hours after giving tPA, as ASA with tPA does not improve outcomes and increases bleed risk[1]
  • Do not give acutely heparin (or any anticoagulation) if giving tPA[2]

Dosing:

  • 0.9mg/kg IV (max 90mg total)
    • 10% of dose is administered as bolus; rest is given over 60min
  • Neuro check Q15min x 2hr
  • No anticoagulation/antiplatelets x 24hr
  • Blood pressure (keep SBP <180, DBP <105)

If SBP is >180-230 or DBP is >120:

  • Nicardipine 5 mg/hr by slow infusion (50 mL/hr) initially; may be increased by 2.5 mg/hr every 15 minutes; not to exceed 15 mg/hr OR
  • Labetalol 10mg IV over 1–2 min; repeat dose q10–20min up to 300mg max OR
  • Labetalol 10mg IV followed by infusion at 2–8 mg/min

If BP not controlled by above measures:

  • Nitroprusside 0.5–10mcg/kg/min
  • Continuous arterial monitoring advised
  • Use with caution in patients with hepatic or renal insufficiency

Thrombolysis in Pulmonary Embolism

See Also

References

  1. Zinkstok SM, Roos YB, ARTIS Investigators . Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet (2012) 380(9843):731–7.10.1016/S0140-6736(12)60949-0.
  2. Periprocedural Antithrombotic Treatment During Acute Mechanical Thrombectomy for Ischemic Stroke: A Systematic Review. Rob A. van de Graaf, Vicky Chalos, Gregory J. del Zoppo, Aad van der Lugt, Diederik W. J. Dippel, Bob Roozenbeek. Front Neurol. 2018; 9: 238.